Press Releases

Summary ToggleProLung, Inc. Announces Addition of Future Board Members

September 19, 2018

Additions Bring Extensive Operating Experience in Medical Technology and Diagnostics as well as Repeated Success with the FDA Approval Process SALT LAKE CITY, UT / ACCESSWIRE / September 19, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') today announced the appointment of Rob Farnsworth and

Summary ToggleLetter to Shareholders (Sept 2018) from Jared Bauer, interim CEO

September 13, 2018

Dear ProLung Shareholders and Colleagues, I have accepted the position of interim CEO of ProLung, Inc.  It is an honor to be given the opportunity to work with each of you and to lead ProLung in its next

Summary ToggleProLung, Inc. Announces Organizational Changes to Sharpen Focus on Achieving FDA Approval and Successful Commercialization

September 13, 2018

Jared Bauer Named Interim CEO and Details Seven-Point Go-Forward Strategy SALT LAKE CITY, UT / ACCESSWIRE / September 13, 2018 /  ProLung, Inc. ("ProLung" or the "Company") today announced the Company is taking significant steps to better align its product, regulatory, marketing, and consulting

Summary ToggleProLung, Inc. Releases Communication Urging Stockholders Not to Respond to Consent Solicitation by Steven C. Eror

August 27, 2018

SALT LAKE CITY, UT / ACCESSWIRE / August 27, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') today released a communication urging stockholders to fill out and return the GOLD consent revocation card from the Company, which they can use to decline or revoke consent to the actions proposed by

Summary ToggleProLung, Inc. Releases Communication Urging Stockholders Not to Respond to Consent Solicitation by Steven C. Eror

August 15, 2018

SALT LAKE CITY, UT / ACCESSWIRE / August 15, 2018 / ProLung, Inc. (“ProLung” or the “Company”) today released a communication urging stockholders not to respond to the consent solicitation by Steven C. Eror. The Company announced that stockholders will soon receive consent revocation materials and

Summary ToggleProLung Recognized with "2018's Most Innovative Predictive Analytics Award" by Corporate Vision

June 18, 2018

SALT LAKE CITY, UT / ACCESSWIRE / June 18, 2018 / Corporate Vision announced that ProLung, Inc. ("ProLung" or the "Company") is their "2018's Most Innovative Predictive Analytics Award - USA" winner.   Andy Robertson, Chief Marketing Officer of ProLung® stated, "Earning this innovation award is

Summary ToggleProLung Named Top Ten Analytics Solution Provider by Pharma Tech Outlook

May 30, 2018

ProLung is very excited to have our Company and product, the ProLung Test™, featured in Pharma Tech Outlook’s May 2018 Special Issue on Pharma Analytics. Named as a Top Ten Analytics Solution Provider in 2018, we are eager to continue preparing for commercialization and pursuing a bold strategy to

Summary ToggleProLung recognized with '2018 Utah Innovation Award' by Stoel Rives and Utah Technology Council

May 01, 2018

SALT LAKE CITY, UT / ACCESSWIRE / May 1, 2018 / Stoel Rives LLP and the Utah Technology Council (UTC) announced that ProLung, Inc. (''ProLung'' or the ''Company'') is their 2018 Utah Innovation Award winner for the ''Life Science - BioTech'' category. Steven Eror, President and CEO of ProLung®

Summary ToggleMDDI Feature: ProLung Breathes Life Into Lung Cancer Detection

April 30, 2018

ProLung is hoping to change the way lung cancer is detected through its test that measures the difference in conductivity between malignant and benign lung tissue.   Courtesy of ProLung Three years ago, the U.S. Preventative Services Task Force and Centers for Medicare and Medicaid Services added

Summary ToggleProLung Recognized with '2018 Biotechnology Award' by Global Health & Pharma

April 23, 2018

SALT LAKE CITY, UT / ACCESSWIRE / April 23, 2018 / Global Health and Pharma (GHP) announced that ProLung, Inc. (''ProLung'' or the ''Company'') is their 2018 Biotechnology Award winner for '' Best Medical Technology Company 2018 - USA and Best Lung Cancer Predictive Analytics Risk Testing Platform